Explore

Trendline Trendline
Diakonos Oncology Presents Promising Glioblastoma Survival Data and Launches Melanoma Study at ASCO

Diakonos Oncology Presents Promising Glioblastoma Survival Data and Launches Melanoma Study at ASCO

Diakonos Oncology Presents Promising Glioblastoma Survival Data and Launches Melanoma Study at ASCO
Rapid Read Rapid Read
New Cancer Treatments Unveiled at ASCO Conference in Chicago

New Cancer Treatments Unveiled at ASCO Conference in Chicago

The American Society of Clinical Oncology (ASCO) annual meeting in Chicago showcased significant advancements in cancer treatment. Key highlights included a new drug, GRWD5769, which helps expose cancer cells to the immune system, and a daily pill, daraxonrasib, that doubles survival time for pancreatic cancer patients. The conference also discussed a genomic test that could allow some breast cancer patients to skip chemotherapy. These developments represent promising steps forward in cancer treatment, offering new hope for patients with previously limited options.
Rapid Read Rapid Read
Cancer Research Advances Highlight Incremental Progress in Treatment

Cancer Research Advances Highlight Incremental Progress in Treatment

Recent advancements in cancer research have shown promising developments in detection methods, drugs, and treatments. Survival rates in the UK have doubled since the 1970s, and Michelle Mitchell of Cancer Research UK highlights a 'golden age' for cancer research, marked by incremental progress rather than a singular breakthrough. A new drug, daraxonrasib, has shown promise in doubling survival time for pancreatic cancer patients, and new immunotherapies are being developed to spare bladder cancer patients from invasive surgeries. These developments were discussed at the American Society of Clinical Oncology meeting in Chicago.
Rapid Read Rapid Read
Richard Scolyer's Legacy in Cancer Research and Advocacy

Richard Scolyer's Legacy in Cancer Research and Advocacy

Professor Richard Scolyer, a renowned melanoma pathologist and cancer researcher, has passed away at the age of 59 after a battle with brain cancer. Scolyer was diagnosed with grade-four glioblastoma in 2023 and became the first patient to receive experimental brain cancer treatment based on melanoma science. His pioneering work in immunotherapy has significantly improved outcomes for advanced melanoma patients. Scolyer was named Australian of the Year in 2024 and was a strong advocate for continued investment in cancer research.
Rapid Read Rapid Read
Australian Doctor's Experimental Cancer Treatment Sparks U.S. Clinical Trial

Australian Doctor's Experimental Cancer Treatment Sparks U.S. Clinical Trial

Pioneering Australian doctor Richard Scolyer, known for his groundbreaking work in cancer treatment, has passed away after a battle with an aggressive brain tumor. Scolyer, alongside Professor Georgina Long, developed an experimental treatment for glioblastoma, a type of brain cancer, based on their successful research in melanoma. This treatment involved a combination of pre-surgery immunotherapy and a personalized vaccine, marking a world-first approach. Despite the low odds of a cure, the treatment aimed to extend Scolyer's life and showed promising results, leading to the initiation of a small clinical trial in the United States. Scolyer's journey and contributions have been widely recognized, including being named Australian of the Year in 2024.
Rapid Read Rapid Read
Breakthrough in Colorectal Cancer Treatment with Immunotherapy

Breakthrough in Colorectal Cancer Treatment with Immunotherapy

Researchers have announced a significant breakthrough in colorectal cancer treatment, revealing that certain tumors can be eradicated using immunotherapy alone, without the need for chemotherapy or surgery. This development, highlighted by Memorial Sloan Kettering Cancer Center, focuses on colorectal cancers with deficient mismatch repair (dMMR) or high microsatellite instability (MSI-H). Early clinical trials have shown complete tumor remission in some patients, suggesting a potential shift towards less invasive treatment options. This approach could reduce the need for surgeries, which often result in life-altering consequences such as colostomies and long-term bowel dysfunction.
Rapid Read Rapid Read
Memorial Sloan Kettering Cancer Center's Immunotherapy Breakthrough Offers New Hope for Colorectal Cancer Patients

Memorial Sloan Kettering Cancer Center's Immunotherapy Breakthrough Offers New Hope for Colorectal Cancer Patients

Recent clinical research conducted by Memorial Sloan Kettering Cancer Center has revealed a significant breakthrough in the treatment of colorectal cancer. The study highlights the potential of immunotherapy, specifically PD-1 inhibitors, to achieve complete tumor remission in certain colorectal cancers characterized by deficient mismatch repair (dMMR) or high microsatellite instability (MSI-H). This development is particularly noteworthy as it suggests that some patients with locally advanced rectal cancer could experience full clinical responses without the need for chemotherapy, radiation, or surgery. The implications of this research are profound, as traditional surgical treatments for rectal cancer often result in life-altering consequences, such as colostomies and long-term bowel dysfunction. If these findings are confirmed in larger trials, immunotherapy could become a new standard of care for select patients, offering a less invasive and more personalized treatment option.
Rapid Read Rapid Read
New Cancer Treatments Highlighted at ASCO Conference Offer Hope and Challenges

New Cancer Treatments Highlighted at ASCO Conference Offer Hope and Challenges

At the 2026 American Society of Clinical Oncology (ASCO) annual meeting in Chicago, researchers presented promising new cancer treatments. Highlights included a smart drug, GRWD5769, which helps immunotherapy drugs expose and attack cancer cells, showing significant tumor reduction in trials. Another breakthrough was a pill, daraxonrasib, doubling survival time for pancreatic cancer patients. Additionally, a genomic test could allow many breast cancer patients to skip chemotherapy. However, challenges remain, such as a failed blood test trial for early cancer detection and a predicted shortage of cancer care workers by 2050 due to rising cancer cases.
Trendline Trendline
Onchilles Pharma Begins Phase 1/2 Trial of N17350 for Advanced Solid Tumors

Onchilles Pharma Begins Phase 1/2 Trial of N17350 for Advanced Solid Tumors

Onchilles Pharma Begins Phase 1/2 Trial of N17350 for Advanced Solid Tumors
Trendline Trendline
Mevion Medical Systems Introduces Compact Proton Therapy at Stanford Medicine

Mevion Medical Systems Introduces Compact Proton Therapy at Stanford Medicine

Mevion Medical Systems Introduces Compact Proton Therapy at Stanford Medicine
Rapid Read Rapid Read
Study Links GLP-1 Weight-Loss Drugs to Reduced Breast Cancer Risk

Study Links GLP-1 Weight-Loss Drugs to Reduced Breast Cancer Risk

Recent research presented at the 2026 American Society of Clinical Oncology Annual Meeting suggests that GLP-1 weight-loss drugs, including Ozempic and Wegovy, may reduce the risk of breast cancer by approximately 30%. The study involved over 110,000 women and found that those taking these medications were significantly less likely to develop breast cancer compared to those who were not. The findings, while observational, add to a growing body of evidence that these drugs could serve as potential cancer prevention tools. Researchers are planning a multisite clinical trial to further investigate this potential benefit.
Trendline Trendline
ADC Therapeutics Faces Setback as Patient Deaths Impact Zynlonta Trial

ADC Therapeutics Faces Setback as Patient Deaths Impact Zynlonta Trial

ADC Therapeutics Faces Setback as Patient Deaths Impact Zynlonta Trial